Investigation Report on China’s Caspofungin Market 2021-2025

$2,600$3,900

Due to the impact of COVID-19 on the overall diagnosis and treatment services of Chinese hospitals, the sales value of Caspofungin in the Chinese market decreased to CNY 801 million in 2020 and the CAGR of Caspofungin in sales value from 2016 to 2020 is 15.45%.

Clear

Description

Caspofungin is the first echinocandin antifungal drug. It has a broad antibacterial spectrum, a long half-life, a high binding rate to human serum proteins, and a few adverse reactions. It is known as the trump card in the systemic antifungal drug market. The drug is an anti-fungal infection drug currently recommended by clinical guidelines in various countries and is widely marketed worldwide. Caspofungin was originally developed by Merck Sharp & Dohme. It was launched in the United States and Europe in 2001. It was launched in China under the trade name CANCIDAS in 2002. By 2020, Caspofungin has been included in China’s Class B medical insurance. There are 4 manufacturers in the Chinese market in 2020, which are Merck Sharp & Dohme (IA) Corp, Merck Sharp & Dohme Ltd, Jiangsu Hengrui Medicine Co., Ltd., and Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

According to CRI’s market research, the sales value of Caspofungin in the Chinese market increased year by year from 2016 to 2019. Due to the impact of COVID-19 on the overall diagnosis and treatment services of Chinese hospitals, the sales value of Caspofungin in the Chinese market decreased to CNY 801 million in 2020 and the CAGR of Caspofungin in sales value from 2016 to 2020 is 15.45%.

CRI expects that with the relief of COVID-19, the sales of Caspofungin in the Chinese market will have a restorative growth from 2021 to 2025. In addition, Caspofungin has the characteristics of broad antifungal spectrum, excellent curative effect and high safety. Based on these advantages, the sales value and sales volume of Caspofungin in the Chinese market still has room to rise. By the first half of 2021, in addition to the original research companies, a total of 5 domestic companies have been approved, including Huadong Medicine Co.,Ltd., Borui Pharmaceutical Technology Development Co., Ltd., Jiangsu Hengrui Medicine Co., Ltd., Chia Tai Tianqing Pharmaceutical Group Co., Ltd. and Haisco Pharmaceutical Group Co., Ltd. It is expected that with the addition of new manufacturers, the sales value of Caspofungin will continue to rise.

 

Topics Covered:

  • -The impact of COVID-19 on China’s Caspofungin market
  • – Sales value of China’s Caspofungin 2016-2020
  • – Competitive landscape of China’s Caspofungin market
  • – Prices of Caspofungin in China
  • – Prices of Caspofungin in China by regions and manufacturers
  • – Analysis on factors affecting the development of China’s Caspofungin market
  • – Prospect of China’s Caspofungin market from 2021 to 2025

Additional information

Publisher

Geography Covered

Date Published

Pages

Charts

Format

Base Year

2016

Base Market Size

450.60

Currency/Unit

CNY million

Forecast Year

2025

Market Size Forecast

1831.60

CAGR

16.86%

Table of Contents

1 Relevant Concepts of Caspofungin

  • 1.1 Indications for Caspofungin
  • 1.2 Development of Caspofungin in China
  • 1.3 Governmental Approval of Caspofungin in China
  • 1.4 The Impact of COVID-19 on Caspofungin sales in China

 

2 Sales of Caspofungin in China, 2016-2020

  • 2.1 Sales Value of Caspofungin
  • 2.1.1 Overall Sales Value
  • 2.1.2 Sales Value by Region
  • 2.2 Sales Volume of Caspofungin
  • 2.2.1 Overall Sales Volume
  • 2.2.2 Sales Volume by Region
  • 2.3 Sales of Caspofungin by Dosage Form in China, 2016-2020
  • 2.3.1 Injection
  • 2.3.2 Analysis of Other Dosage Forms

 

3 Analysis of Major Caspofungin Manufacturers in China in 2020

  • 3.1 Analysis of Market Share of Major Caspofungin Manufacturers
  • 3.1.1 Investigation on Market Share by Sales Value
  • 3.1.2 Investigation on Market Share by Sales volume
  • 3.2 Merck Sharp & Dohme (I.A.) Corp
  • 3.2.1 Enterprise Profile
  • 3.2.2 Sales of CANCIDAS (Merck Sharp & Dohme (I.A.) Corp’s Caspofungin) in China
  • 3.3  Merck Sharp & Dohme Ltd
  • 3.3.1 Enterprise Profile
  • 3.3.2 Sales of CANCIDAS (Merck Sharp & Dohme Ltd’s Caspofungin) in China
  • 3.4 Jiangsu Hengrui Medicine Co., Ltd.
  • 3.4.1 Enterprise Profile
  • 3.4.2 Sales of Kajing (Jiangsu Hengrui Medicine Co., Ltd. ’s Caspofungin) in China
  • 3.5 Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
  • 3.5.1 Enterprise Profile
  • 3.5.2 Sales of Tianming (Chia Tai Tianqing Pharmaceutical Group Co., Ltd.’s Caspofungin) in China

 

4 Prices of Caspofungin for Different Manufacturers in China, 2020-2021

  • 4.1 Merck Sharp & Dohme (I.A.) Corp (CANCIDAS)
  • 4.2 Merck Sharp & Dohme Ltd (CANCIDAS)
  • 4.3 Jiangsu Hengrui Medicine Co.,Ltd. (Kajing)
  • 4.4 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (Tianming)

 

5 Prospect of Chinese Caspofungin drug Market, 2021-2025

  • 5.1 Influential Factors of Chinese Caspofungin Market Development
  • 5.1.1 The Impact of COVID-19 on Chinese Caspofungin Market
  • 5.1.2 Market Drivers and Opportunities
  • 5.1.3 Market Threats and Challenges
  • 5.2 Forecast on Market Size
  • 5.3 Forecast on Market Trend

 

List of Charts

  • Chart Patent Information About Caspofungin Injection Registration in China
  • Chart Sales Value of Caspofungin Injection over the World
  • Chart Sales Value of Caspofungin Injection in China, 2016-2020
  • Chart Sales Value of Caspofungin Injection in China by Region, 2016-2020
  • Chart Sales Volume of Caspofungin Injection in China, 2016-2020
  • Chart Sales Volume of Caspofungin Injection in China by Region, 2016-2020
  • Chart Market Share by Sales Value of Top Caspofungin Manufacturers in China, 2016-2020
  • Chart Sales Value and Volume of CANCIDAS (Merck Sharp & Dohme (I.A.) Corp’s Caspofungin) in China, 2016-2020
  • Chart Sales Value and Volume of (Merck Sharp & Dohme Ltd’s Caspofungin) in China, 2016-2020
  • Chart Sales Value and Volume of Kajing in China, 2016-2020
  • Chart Sales Value and Volume of Tianming in China, 2016-2020
  • Chart Referential Prices of CANCIDAS (Merck Sharp & Dohme (I.A.) Corp’s Caspofungin) in China, 2020-2021
  • Chart Referential Prices of CANCIDAS (Merck Sharp & Dohme Ltd’s Caspofungin) in China, 2020-2021
  • Chart Referential Prices of Kajing in China, 2020-2021
  • Chart Referential Prices of Tianming in China, 2020-2021
  • Chart Forecast on Sales Value of Caspofungin in China, 2021-2025
  • Chart Forecast on Sales Volume of Caspofungin in China, 2021-2025